IDH3A and glioma: We observed significant differences in the DMS between glioma patient groups stratified by WHO grade (P < 0.001), survival status (P < 0.001), age (P < 0.05), 1p/19q status (P < 0.001), and isocitrate dehydrogenase (IDH) status (P < 0.01; Supplementary Figure 7A).